KIT to help Korean drugs gain U.S. FDA approval

The U.S. Food and Drug Administration has recently approved the preclinical data submitted by a local non-clinical contract research organization, which will help Korean drug firms increase their share of the U.S. pharmaceutical market.

The Korea Institute of Toxicology (KIT) has since 2005 offered a full range of non-clinical study services for Dong-A PharmTech’s Zydena, an erectile dysfunc...